1 CRISPR-Cas9 genome editing is revolutionizing fundamental research and has great potential for 2
Introduction 41 CRISPR (clustered, regularly interspaced, short palindromic repeat)-Cas (CRISPR-associated) 42 genome editing has rapidly become a widely used tool in molecular biology laboratories. Its ease 43 of use and high flexibility allows researchers to modify and edit genomes in cell lines (1), stem 44 cells (2), animals and plants (3, 4) , and even human embryos (5). At least two components must 45 be successfully delivered into cells during genome editing: the Cas protein, such as Cas9, and a 46 guide RNA (gRNA) to direct the Cas protein to its target site. For in vitro cultured cells this can 47 be done by transfecting plasmids encoding gRNA and Cas9 protein. However, transfection of 48 plasmid DNA into sensitive cell types such as primary and stem cells is challenging and inefficient. 49
The introduction of plasmids can also lead to undesired integration of DNA at the cut site (6), 50 increased off-target activity through prolonged expression of the CRISPR-Cas9 components (7), 51 and a delay in editing while the cell expresses gRNA and Cas protein (8). 52
53
The delivery of gRNA and Cas9 protein as a pre-complexed ribonucleoprotein (RNP) sidesteps 54 issues related to plasmid expression and has proved to be a successful strategy to edit human 55 primary cells, including T cells (9,10), hematopoietic stem cells (11) (12) (13) (14) , and neurons (15). This 56 makes RNP editing a particularly attractive approach for therapeutic applications, but relatively 57 little is known about the non-editing consequences of introducing a foreign gRNA and Cas9 58 protein. Human cells have evolved multiple defense mechanisms to guard against foreign 59 components, and genome editing reagents have the potential to activate these systems. For 60 example, recent data suggests that humans may have a pre-existing adaptive immune response to 61 the Cas9 protein (16). But cellular responses to the gRNAs used to program Cas9 editing have so 62 far not been well explored. 63 5 Cells respond to infection by RNA-viruses with an innate immune response that protects the host 64 cell from invading foreign genetic material (17). Foreign RNAs are recognized by pathogen-65 associated molecular pattern (PAMP) binding receptors in the cytosol that include retinoic acid-66 inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) (18). This 67 triggers a cascade of events mediated by the mitochondrial activator of virus signaling (MAVS) 68 protein resulting in the transcriptional activation of type I interferons and interferon-stimulated 69 genes (ISGs) (19-21). 70 71 PAMPs usually contain exposed 5'-triphosphate ends (18), which may also be present in gRNAs 72 made via T7 in vitro transcription (IVT) (22,23). We asked whether IVT gRNAs cause an innate 73 immune response, and here show that RNP genome editing induces upregulation of interferon beta 74 (IFNb) and interferon-stimulated gene 15 (ISG15) in a variety of human cell types. This activity 75 depends upon RIG-I and MAVS, but is independent of MDA5. The extent of the immune response 76 depends upon the protospacer sequence, but removal of the 5'-triphosphate from gRNAs avoids 77 stimulation of innate immune signaling. The potential for Cas9 RNP editing to induce an antiviral 78 response indicates that care must be taken when designing therapeutic strategies to edit primary 79 cells. 80
81

Results
82
To investigate if mammalian cells react to IVT gRNA/Cas9 with an innate immune response, we 83 first performed genome editing in human embryonic kidney 293 (HEK293) cells using Cas9 RNPs. 84
To separate innate immune response from genome editing, we performed these experiments with 85 a non-targeting gRNA that recognizes a sequence within BFP and has no known targets within the 86 6 human genome (24). Constant amounts of recombinant Cas9 protein were complexed with 87 different amounts of non-targeting IVT gRNA and RNPs were transfected into HEK293 cells using 88 CRISPRMAX lipofection reagent (25). We harvested cells 30h after transfection and measured 89 transcript levels of IFNB1 and ISG15 by qRT-PCR ( Figure 1A) . Introduction of gRNAs caused a 90 dramatic increase in both IFNB1 and ISG15 levels, and the presence of Cas9 protein did not have 91 an effect on the outcome. Cas9 on its own did not induce IFNB1 or ISG15 expression. To our 92 surprise, as little as 1 pmol of gRNA was sufficient to trigger a 30-50-fold increase in the 93 transcription of innate immune genes. We further found that the commonly-administered 100 pmol 94 of a gRNA can induce IFNB1 by 4,000 fold, which is equal to or even stronger than induction by 95 canonical IFNb inducers such as viral mRNA from Sendai Virus (26) or a Hepatitis C virus (HCV) 96 PAMP (20,27) ( Figure 1B) . 97 98 RNPs can be delivered into cells via different transfection methods and while lipofection is cost-99 effective and easy to use, many researchers prefer electroporation for harder-to-transfect cells. We 100 wondered if the transfection method would affect the IFNb response and compared gRNA 101 transfection via lipofection (Lipofectamine 2000 and RNAiMAX) to nucleofection (Lonza) 102 ( Figure 1C) . Lipofection led to a strong increase in IFNB1 and ISG15 transcript levels after as 103 little as 6h post transfection, and the response was sustained for up to 48 hours. Nucleofection also 104 caused an increase in innate immune signaling at early time points, but the response was much 105 milder than in lipofected samples and was greatly diminished by 48 hours. 106 107 Next, we asked if the innate immune response to gRNAs is a common phenomenon across different 108 cell types and compared IFNb activation in seven commonly used human cell lines of various 7 lineages: HEK293T, HEK293, HeLa, Jurkat, HCT116, HepG2 and K562 (Figure 2A) . While the 110 magnitude of induction varied between cell lines, all tested cell lines responded to IVT gRNA 111 transfection with activation of IFNB1 expression. The sole exception was K562 cells, which have 112 a homozygous deletion of the IFNA and IFNB1 genes (28). We also measured transcript levels of 113 two major cytosolic pathogen recognition receptors, RIG-I (DDX58) and MDA5 (IFIH1), and 114 noticed that all cell lines except K562 upregulated these transcripts in response to introduction of 115 gRNAs. We also confirmed these results on the protein level in HEK293 cells ( Figure 2B) . if different 20 nucleotide protospacers in gRNAs vary in their potency to trigger an innate immune 131 8 and transfected into HEK293 cells. Surprisingly, we found that the cells responded to different 133 protospacers with a wide range of differential IFNB1 expression. Several gRNAs produced very 134 little innate immune response, and one gRNA (gRNA11) yielded no IFNB1 activation at all 135 ( Figure 3A) . We speculated that the differential response may be correlated with the purity of the 136 RNA product after IVT or the stability of the secondary structure of the RNA (31). However, we 137 found that there was no obvious correlation between the immune response to certain gRNAs and 138 their purity, predicted protospacer secondary structure, full secondary structure including the 139 We asked if preparations that remove the 5' triphosphate might avoid or reduce the innate immune 146 response to IVT gRNAs. We first used a synthetic gRNA that lacks a 5'-triphosphate and verified 147 that this gRNA does not induce IFNB1 expression when transfected into HEK293 cells ( Figure  148 3B). Synthetic guide RNAs are becoming more commonplace, but are still an order of magnitude 149 more expensive than IVT of gRNAs. This limits their application for high-throughput interrogation 150 of gene function in primary cells. We therefore asked if treatment of IVT gRNA with calf intestinal 151 alkaline phosphatase (CIP) to remove the 5'-triphosphate would reduce IFNB1 induction. We 152 found that CIP treatment significantly reduced the IFNB1 response ( Figure 3B ). Using different 153 CIP treatment regimes, we further found that removal of the 5'-triphosphate must to be absolutely 154 complete and should be carried out rigorously to avoid IFN stimulation (Supplementary Figure 9 A-B). We also compared purification of IVT gRNAs by solid phase reversible immobilization 156 (SPRI) beads to column purification and established that SPRI bead clean-up is not sufficient to 157 completely avoid an immune response even when more CIP is used ( Figure 3B and 158 Supplementary Figure 3C) . Taken together, these results indicate that 5'-triphosphate is a 159 necessary requirement for gRNA-induced IFNB1 activation through RIG-I, but that additional 160 structural properties of the gRNAs also influence the magnitude of the immune response. 161 162 When a cell initiates an antiviral immune response, it also undergoes cellular stress that can affect 163 cell viability (33,34). Hence, we asked if there is a correlation between the IFNb response and cell 164 viability after transfection with synthetic, IVT or CIP-treated IVT gRNA. Not surprisingly, the 165 viability of the very robust HEK293 cell line was not affected by the antiviral immune response 166 (Supplementary Figure 3D) . We then turned to primary CD34 + human hematopoietic stem and 167 progenitor cells (HSPCs), which are a much more sensitive cell type. We first nucleofected HSPCs 168 with RNPs targeting the HBB gene (11) and compared synthetic and IVT gRNA interferon 169 stimulation and cell viability post transfection. Double-strand breaks have been reported to cause 170 innate immune stimulation and can themselves cause decreases in cell fitness (35, 36) . Therefore, 171
we performed controls using nuclease-dead Cas9 (dCas9) to form RNPs. We saw a significant 172 decrease in cell viability of HSPCs in both IVT gRNA RNP samples which was associated with 173 an increase in IFN stimulated genes ISG15 and RIG-I (Figure 3C-D) . We did not see a substantial 174 difference in viability or ISG expression between Cas9 and dCas9 RNPs suggesting that nuclease 175 activity did not affect the immune response. Next, we asked if CIP treatment of gRNAs could 176 reverse the decrease in viability in HSPCs. We nucleofected HSPCs with dCas9 RNPs targeting a 10 non-coding intron of JAK2 and compared synthetic, IVT and CIP-treated IVT gRNAs. Strikingly, 178 CIP treatment could completely restore the viability in HSPCs (Figure 3E) . 179 180 Discussion 181 We have found that IVT gRNAs used with Cas9 RNPs for many genome editing experiments can 182 trigger a strong innate immune response in many mammalian cell types (Figure 4) We found that synthetic gRNAs completely circumvent the RIG-I mediated response, offering a 201 valuable path to avoid innate immune signaling during therapeutic editing. However, synthetic 202 gRNAs can become expensive when performing experiments that require testing or using many 203 gRNAs. We found that a cost-effective CIP treatment to remove the 5'-triphosphate before 204 transfection reduces the immune response and increases post-transfection viability in HSPCs. 205
Complete removal of the 5'-triphosphate is essential to restore viability in HSPCs to the same level 206 as observed with synthetic gRNAs. Thus, consideration of a potential innate immune stimulation 207 prior to choice of genome editing reagents, study design, and implementation of controls is critical 208 when performing genome editing using RNPs in mammalian cells. 209
Double-strand breaks have on their own been reported to induce an innate immune response (35). 210
However, we performed controls comparing WT Cas9 to a nuclease-dead Cas9 thereby showing 211 that the gRNA-mediated innate immune response and associated cell death in HSPCs is not caused 212 by double-strand breaks. 213 214 While we were preparing this manuscript for submission, the Kim group reported similar results 215 in HeLa cells and primary human CD4 + T cells (38). They confirmed that the type I interferon 216 response is dependent on the presence of a 5'-triphopsphate group and that CIP treatment can 217 increase viability by avoiding the antiviral response. These results are very much in alignment with 218 our findings and extend the potential problem of innate immune signaling to additional cell types. 219
220
Our study adds extra depth by further outlining the mechanisms by which gRNAs are sensed. We 221
show that gRNA sensing depends upon RIG-I and MAVS, but MDA5 knockout cells are fully 222 capable of inducing IFNb after IVT gRNA transfection. Hence, gRNA sensing is independent of 223 the MDA5 PAMP receptor. Furthermore, we show that in addition to a 5'-triphosphate, the 224 protospacer sequence is also critical to determine the intensity of the IFNb response. Not only do 225 different gRNAs induce different innate immune responses, some gRNAs induce no response at 226 all. It has been proposed that 5'-basepaired RNA structures are required to activate antiviral 227 signaling via RIG-I, but we found no correlation between signaling and a variety of predicted RNA 228 properties, including secondary structure (31). Our results therefore suggest that the mechanism of 229 gRNA sensing by the RIG-I pathway is relatively complex, in that it requires 5' triphosphates but 230 that this moiety is not sufficient to induce the response. Future work to delineate the full set of 231 Chemically synthesized gRNAs, which were purified using high-performance liquid 288 chromatography (HPLC), were purchased from Synthego. For CRISPR/Cas9 genome editing we used a plasmid encoding both the Cas9 protein and the 349 gRNA. pSpCas9(BB)-2A-GFP (px458) was a gift from Feng Zhang (Addgene plasmid #48138). 350
We designed gRNA sequences using the free CRISPR knockout design online tool from Synthego. 351 Two different gRNA sequences were designed for RIG-I and MDA5, respectively (see 352 Supplementary Table 3) . 353 2x10 5 HEK293 cells were nucleofected with 2 µg of px458 plasmids containing both targeting 354 gRNAs in a 1:1 ratio using a Lonza 4D nucleofector (Lonza) with the manufacturer's 355 recommended settings. After 48h cells were harvested and subjected to fluorescence-activated cell 356 sorting (FACS). Cells expressing high levels of GFP were single-cell sorted into 96-well plates to 357 establish clonal populations. 358
For the screening process, genomic DNA from clonal populations was extracted using 359 QuickExtract solution (Lucigen). For KO of RIG-I and MDA5 we screened clones by genomic 360 PCR looking for a PCR product that is significantly smaller in size than that of WT HEK293 cells 361 (see Supplementary Table 4 for 
